Equity (Tables)
|
12 Months Ended |
Dec. 31, 2021 |
|---|
| Banking Regulation, Total Capital [Abstract] |
|
| Schedule of breakdown of the company’s share capital |
|
|
|
December 31, 2021
|
|
December 31, 2020
|
| |
|
Issued and outstanding
|
|
Authorized
|
|
Issued and outstanding
|
|
Authorized
|
| |
|
Number of shares
|
| Ordinary Shares, NIS 0.01 par value |
|
16,617,397 |
|
110,714,286 |
|
54,396,834 |
|
690,000,000 |
| Ordinary “A” Shares, NIS 0.01 par value |
|
— |
|
— |
|
— |
|
10,000,000 |
| |
|
16,617,397 |
|
110,714,286 |
|
54,396,834 |
|
700,000,000 |
|
| Schedule of share-based payment balance |
|
|
|
Year Ended December 31, 2021
|
| |
|
Number of
options
|
|
Weighted
Average-
Exercise
Price
|
|
Weighted
Average
remaining
contractual
term in years
|
|
Share options outstanding at beginning of year
|
|
5,544,611 |
|
|
$
|
0.678 |
|
3.82 |
|
1:28 reverse options split(*)
|
|
(5,346,589 |
)
|
|
|
—
|
|
—
|
|
Share options granted during the year
|
|
6,768,045 |
|
|
$
|
0.2304 |
|
9.72 |
|
Share options exercised during the year
|
|
(59,510 |
)
|
|
$
|
0.09 |
|
—
|
|
Share options forfeited/expired during the year
|
|
(142,342 |
)
|
|
$
|
0.6783 |
|
—
|
|
Share options outstanding at end of year
|
|
6,764,215 |
|
|
$
|
0.2972 |
|
9.73 |
|
Share options exercisable at end of year
|
|
2,861,715 |
|
|
$
|
0.2849 |
|
9.71 |
|
|
|
Year Ended December 31, 2020
|
| |
|
Number of
options
|
|
Weighted
Average-
Exercise
Price
|
|
Weighted
Average
remaining
contractual
term in years
|
|
Share options outstanding at beginning of year
|
|
5,860,030 |
|
|
$
|
0.677 |
|
4.59 |
|
Share options forfeited/expired during the year
|
|
(315,419
|
)
|
|
$
|
0.334
|
|
—
|
|
Share options outstanding at end of year
|
|
5,544,611 |
|
|
$
|
0.678 |
|
3.82 |
|
Share options exercisable at end of year
|
|
4,269,167 |
|
|
$
|
0.504 |
|
4.5 |
|
| Schedule of company capital instruments |
|
|
|
Year ended December 31, 2021
|
|
Dividend yield (%)
|
|
0% |
|
Expected volatility in share prices (%)
|
|
56.08% – 77.3% |
|
Risk-free interest rate (%)
|
|
0.10% – 1.401% |
|
Predicted life of share (in years)
|
|
2.25 – 10 |
|
Share price (NIS)
|
|
5.295 – 7.07 |
|
| Schedule of consolidated financial statements |
|
|
|
Year Ended December 31, 2021
|
| |
|
2021
|
|
2020
|
| |
|
U.S. dollars in thousands
|
|
Cost of revenues
|
|
603 |
|
4 |
|
Research and development expenses
|
|
1,607 |
|
89 |
|
Sales and marketing expenses
|
|
1,770 |
|
12 |
|
General and administrative expenses
|
|
3,205 |
|
582 |
|
Total expenses – share-based payments plan
|
|
7,185 |
|
687 |
|